Literature DB >> 12960972

Fetal muscle gene transfer is not enhanced by an RGD capsid modification to high-capacity adenoviral vectors.

R Bilbao1, D P Reay, T Hughes, V Biermann, C Volpers, L Goldberg, J Bergelson, S Kochanek, P R Clemens.   

Abstract

High levels of alpha(v) integrin expression by fetal muscle suggested that vector re-targeting to integrins could enhance adenoviral vector-mediated transduction, thereby increasing safety and efficacy of muscle gene transfer in utero. High-capacity adenoviral (HC-Ad) vectors modified by an Arg-Gly-Asp (RGD) peptide motif in the HI loop of the adenoviral fiber (RGD-HC-Ad) have demonstrated efficient gene transfer through binding to alpha(v) integrins. To test integrin targeting of HC-Ad vectors for fetal muscle gene transfer, we compared unmodified and RGD-modified HC-Ad vectors. In vivo, unmodified HC-Ad vector transduced fetal mouse muscle with four-fold higher efficiency compared to RGD-HC-Ad vector. Confirming that the difference was due to muscle cell autonomous factors and not mechanical barriers, transduction of primary myogenic cells isolated from murine fetal muscle in vitro demonstrated a three-fold better transduction by HC-Ad vector than by RGD-HC-Ad vector. We hypothesized that the high expression level of coxsackievirus and adenovirus receptor (CAR), demonstrated in fetal muscle cells both in vitro and in vivo, was the crucial variable influencing the relative transduction efficiencies of HC-Ad and RGD-HC-Ad vectors. To explore this further, we studied transduction by HC-Ad and RGD-HC-Ad vectors in paired cell lines that expressed alpha(v) integrins and differed only by the presence or absence of CAR expression. The results increase our understanding of factors that will be important for retargeting HC-Ad vectors to enhance gene transfer to fetal muscle.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12960972     DOI: 10.1038/sj.gt.3302084

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  11 in total

1.  The antitumor effects of adenoviral-mediated, intratumoral delivery of interleukin 23 require endogenous IL-12.

Authors:  J Reay; A Gambotto; P D Robbins
Journal:  Cancer Gene Ther       Date:  2011-12-09       Impact factor: 5.987

2.  Enhanced Cytotoxic CD8 T Cell Priming Using Dendritic Cell-Expressing Human Papillomavirus-16 E6/E7-p16INK4 Fusion Protein with Sequenced Anti-Programmed Death-1.

Authors:  Tatiana M Garcia-Bates; Eun Kim; Fernando Concha-Benavente; Sumita Trivedi; Robbie B Mailliard; Andrea Gambotto; Robert L Ferris
Journal:  J Immunol       Date:  2016-02-05       Impact factor: 5.422

3.  Adenoviral gene transfer of a single-chain IL-23 induces psoriatic arthritis-like symptoms in NOD mice.

Authors:  Rafael R Flores; Lana Carbo; Eun Kim; Montina Van Meter; Consuelo M Lopez De Padilla; Jing Zhao; Debora Colangelo; Matthew J Yousefzadeh; Luise A Angelini; Lei Zhang; Enrico Pola; Nam Vo; Christopher H Evans; Andrea Gambotto; Laura J Niedernhofer; Paul D Robbins
Journal:  FASEB J       Date:  2019-06-06       Impact factor: 5.834

4.  Systemic delivery of AAV8 in utero results in gene expression in diaphragm and limb muscle: treatment implications for muscle disorders.

Authors:  B M Koppanati; J Li; X Xiao; P R Clemens
Journal:  Gene Ther       Date:  2009-05-28       Impact factor: 5.250

5.  IL-Y, a synthetic member of the IL-12 cytokine family, suppresses the development of type 1 diabetes in NOD mice.

Authors:  Rafael R Flores; Eun Kim; Liqiao Zhou; Chenjie Yang; Jing Zhao; Andrea Gambotto; Paul D Robbins
Journal:  Eur J Immunol       Date:  2015-09-01       Impact factor: 5.532

6.  Helper-Dependent Adenoviral Vectors.

Authors:  Amanda Rosewell; Francesco Vetrini; Philip Ng
Journal:  J Genet Syndr Gene Ther       Date:  2011-10-29

7.  Retargeted and detargeted adenovirus for gene delivery to the muscle.

Authors:  Tien V Nguyen; Stephanie S Anguiano-Zarate; William E Matchett; Mary E Barry; Michael A Barry
Journal:  Virology       Date:  2017-11-22       Impact factor: 3.616

8.  Gene therapy with helper-dependent adenoviral vectors: current advances and future perspectives.

Authors:  Francesco Vetrini; Philip Ng
Journal:  Viruses       Date:  2010-09-03       Impact factor: 5.818

9.  Peptide targeting of adenoviral vectors to augment tumor gene transfer.

Authors:  E N Ballard; V T Trinh; R T Hogg; R D Gerard
Journal:  Cancer Gene Ther       Date:  2012-05-18       Impact factor: 5.987

10.  Adenoviral-mediated, intratumor gene transfer of interleukin 23 induces a therapeutic antitumor response.

Authors:  J Reay; S-H Kim; E Lockhart; J Kolls; P D Robbins
Journal:  Cancer Gene Ther       Date:  2009-04-24       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.